OPDIVO 300 mg solution for injection

Company
Bristol-Myers Squibb Pharma EEIG
Active Ingredient
Strength
  • 300 mg
Dosage Form
Solution for injection
Legal Category
A - prescription, may not be renewed
Last Updated
25/09/2026

Loading the document

Bristol-Myers Squibb Pharma EEIG

Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland

Telephone
+3531800749749
Email
medical.information@bms.com